Reumatología

2019

1. Altered Th17/treg ratio in peripheral blood of systemic lupus erythematosus but not primary antiphospholipid syndrome

   Frontiers in Immunology, Vol. 10, Núm. MAR

2. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus

   Arthritis Care and Research, Vol. 71, Núm. 5, pp. 579-590

3. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients

   American Journal of Ophthalmology, Vol. 200, pp. 85-94

4. Biallelic loss-of-function LACC1/FAMIN Mutations Presenting as Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis

   Scientific Reports, Vol. 9, Núm. 1

5. Budget impact analysis of subcutaneous belimumab in patients with systemic lupus erythematosus in Spain

   ClinicoEconomics and Outcomes Research, Vol. 11, pp. 757-765

6. Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases

   Annals of the Rheumatic Diseases, Vol. 78, Núm. 10, pp. 1405-1411

7. Combination urate-lowering therapy in the treatment of gout: What is the evidence?

   Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 4, pp. 658-668

8. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

   Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089

9. Discordance between doctor and patient assessments and non-adherence to subcutaneous biological drugs

   Rheumatology International, Vol. 39, Núm. 6, pp. 1077-1082

10. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study

    Arthritis Research and Therapy, Vol. 21, Núm. 1

11. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout

    Drugs in Context, Vol. 8

12. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality

    RMD Open, Vol. 5, Núm. 2

13. Gout

    Nature Reviews Disease Primers, Vol. 5, Núm. 1

14. Gout

    Rheumatic Disease Clinics of North America, Vol. 45, Núm. 4, pp. 583-591

15. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600

16. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout

    Arthritis Care and Research, Vol. 71, Núm. 3, pp. 427-434

17. Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia

    EBioMedicine, Vol. 46, pp. 499-511

18. Healthcare Experience and their Relationship with Demographic, Disease and Healthcare-Related Variables: A Cross-Sectional Survey of Patients with Chronic Diseases Using the IEXPAC Scale

    Patient, Vol. 12, Núm. 3, pp. 307-317

19. Identification of a 3′-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 351-360

20. LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients

    Rheumatology International, Vol. 39, Núm. 11, pp. 1875-1882